PANZYGA

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is used to treat primary humoral immunodeficiency (PI) in patients who are at least 2 years old. This includes conditions such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, and Wiskott-Aldrich syndrome, among others.

The life expectancy of patients with CIDP disease is similar to that of healthy individuals. Factors such as complications, coexisting medical conditions, and treatments have a greater impact on lifespan than CIDP itself. Overall, the long-term prognosis is positive, as only a small percentage of individuals die as a result of the disease or its complications.

Yes, you can receive Panzyga at home. However, it must be administered by a trained healthcare professional as it is given as an IV infusion. You also have the option to receive Panzyga in a hospital or infusion clinic.

Generic Name: immune globulin intravenous, human – ifas liquid preparation.
Brand Name: Panzyga.
Drug Class: Immune Globulins.

Conditions such as myositis, lupus, adult-onset Still’s disease, systemic juvenile idiopathic arthritis, vasculitis, antiphospholipid syndrome, and individuals with certain complications related to Sjögren’s syndrome.

A study conducted in Phoenix has found that subcutaneous efgartigimod PH20 SC is effective and well-tolerated in treating chronic inflammatory demyelinating polyneuropathy (CIDP). This new treatment option offers a more convenient alternative to older treatments, such as intravenous therapy, for patients with this rare disease.

CIDP can manifest as a monophasic, relapsing, or progressive condition, with symptoms developing over a period of eight weeks. This time frame, along with the duration it takes to reach the lowest point of symptoms (nadir), can help differentiate CIDP from Guillain-Barre syndrome (GBS) or other acute inflammatory demyelinating polyneuropathies (AIDP).

The available treatments for CIDP consist of immunosuppressive drugs, steroids, intravenous immunoglobulin, and plasma exchange (plasmapheresis) to eliminate immune system proteins from the bloodstream.

IVIG therapy is designed to restore adequate levels of IgG antibodies that can passively neutralize or opsonize a wide range of infectious pathogens. Additionally, it can activate different immune cells, leading to an active immune response and providing protection against various diseases.

IVIG 10% (Panzyga; Octapharma AG, Vienna, Austria) is a new liquid ready-to-use human immunoglobulin 10% (100 mg mL-1) IVIG product. It is a high-purity, glycine-stabilized formulation that is manufactured using a combination of precipitation and chromatography techniques to harvest and purify immunoglobulin G.

Panzyga® was approved by the FDA in February 2021 as a treatment for adults with CIDP.

Recent investigations in murine models have demonstrated that IVIg can prevent and reduce the symptoms of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and scleroderma. This is believed to be due to the presence of anti-idiotypic antibodies in IVIg, which contribute to its immunomodulatory action.

Generally, SCIG is linked to fewer side effects compared to IVIG. SCIG can be considered when an individual experiences difficulties with IVIG, has limited venous access, or when their lifestyle is better suited for SCIG rather than IVIG.

PANZYGA utilizes glycine as its stabilizer and does not include any preservatives or sucrose.

IVIg can enhance your immune system, enabling you to combat infections and maintain good health. This treatment involves extracting liquid immunoglobulin from healthy donors’ blood plasma, which undergoes rigorous screening to ensure their well-being. Additionally, the plasma is thoroughly tested for major infections such as hepatitis and AIDS.

IVIGs are sterile, purified products made from pooled human plasma. They usually have over 95% unmodified IgG, which has intact Fc-dependent effector functions. They also have very small amounts of IgA or IgM.

The initial infusion rate should be kept constant for 30 minutes. After the initial infusion, if it is well tolerated, the infusion rate can be slowly increased every 15-30 minutes, as long as it is tolerated, until reaching the maximum infusion rate indicated in the table for each specific use.

Panzyga® should be administered using a vented, unfiltered set. It is important to note that a filter is not required, but if one is used, it is recommended to use a pore size of 15 microns or larger to avoid slowing down the infusion. Alternatively, 0.2 micron filters may also be used.

Indication: The dosage for the treatment of Primary Humoral Immunodeficiency (PI) is 300 to 600 mg/kg body weight (3-6 mL/kg) administered every 3 to 4 weeks.

The dosage for the treatment of Chronic Immune Thrombocytopenia (ITP) is 2 g/kg (20 mL/kg), divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days.

PANZYGA should be stored at a temperature range of 36°F to 46°F (2°C to 8°C) for up to 36 months from the date of manufacture. It can also be stored at room temperature (‰¤77°F or 25°C) for up to 12 months within its shelf life.

Caution: This medication can lead to fever, chills, flushing, headaches, nausea, and vomiting, particularly if it is your first time taking it or if you have not taken it for over 8 weeks. If you experience any of these symptoms, seek immediate medical attention from your doctor or nurse.

Headache is a frequently experienced side effect, along with chills, fever, flushing, flu-like muscle or joint pains, fatigue, nausea, vomiting, and rash. These reactions are usually observed after the initial administration of IVIG or when switching to a different brand.

After your first IVIg treatment, it may take days or weeks before you see any improvement in your symptoms. If the treatment is effective for you, you should notice some benefits within 4 weeks. However, it’s important to note that not everyone responds to this treatment.

The effectiveness of IVIg treatment can vary depending on the specific condition and individual response. Generally, it is expected to start showing results within a few weeks. However, the duration of its effects can also vary, with some individuals experiencing benefits for a few months.

Panzyga, an immunoglobulin or antibody, is administered intravenously by a healthcare provider to treat specific immune system-related conditions.

Generic Name: immune globulin intravenous, human – ifas liquid preparation.
Brand Name: Panzyga.
Drug Class: Immune Globulins.

If you have been undergoing IVIG treatment to prevent recurring infections, a positive indication of its effectiveness would be a decrease in the frequency and severity of your infections. This reduction in infections suggests that the IVIG treatment is bolstering your immune system and improving your body’s ability to combat pathogens.

For PI, as tolerated, the infusion rate of 14 mg/kg/min is the only one approved by the FDA for PANZYGA.

Privigen is a medication that aids in boosting the immune system of two primary patient groups. These groups include individuals who are susceptible to infections due to a deficiency in antibodies, which are proteins in the blood that assist the body in combating diseases.

You can give Privigen as a maintenance infusion of 1 g/kg (10 mL/kg) in a single infusion on one day or split into two doses over two consecutive days, every 3 weeks.

IVIG is recommended as the initial treatment for certain conditions, including primary immunodeficiencies, Kawasaki’s disease, Guillain-Barre syndrome, and idiopathic immune thrombocytopenia (ITP).

In a FcγRIIB receptor-dependent manner, intravenous immunoglobulin (IVIG) enhances brain repair and enhances cognitive outcomes following traumatic brain injury.

Caution: This medication has the potential to cause severe (rarely fatal) kidney issues. The risk is elevated if you have pre-existing kidney problems, diabetes, or a serious blood infection.

IVIg may result in elevated blood pressure, potentially increasing the risk of heart attack or stroke, as well as the risk of blood clots. If you have any concerns about your treatment or its side effects, it is important to talk to your doctor, rheumatology nurse, or pharmacist.

Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura (ITP) in individuals aged 15 years and above, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

Hizentra is approved for patients who are 2 years of age or older. However, the safety and effectiveness of Privigen have not been determined for patients with PI who are under 3 years of age. Additionally, Privigen can be used to increase platelet counts in patients with chronic immune thrombocytopenic purpura (ITP).

Weight gain from IVIG is not frequently reported in clinical studies. However, individual experiences may vary due to factors such as metabolism, other medical conditions, concurrent medication use, and predisposition to weight gain.

Headache is a frequently experienced side effect, along with chills, fever, flushing, flu-like muscle or joint pains, fatigue, nausea, vomiting, and rash. These reactions are usually observed after the initial administration of IVIG or when switching to a different brand.

Intravenous immunoglobulin (IVIg) is a therapeutic preparation of polyspecific human IgGs that are purified from plasma collected from numerous individuals. When given in high doses, IVIg has the ability to suppress inflammation and has been shown to be effective in treating a range of autoimmune and systemic inflammatory conditions.

Privigen is a type of immune globulin.

IVIG is utilized for the treatment of a range of autoimmune, infectious, and idiopathic conditions. It has been approved as a treatment option for multifocal motor neuropathy, chronic lymphocytic lymphoma, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, and ITP.